

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4814953

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BIOCEUTICALS ARZNEIMITTEL AG	07/04/2011
RECEIVING PARTY DATA	
Name:	INNOVATIVE PROTEINS CORPORATION
Street Address:	16192 COASTAL HWY
City:	LEWES
State/Country:	DELAWARE
Postal Code:	19958
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15728692
CORRESPONDENCE DATA	
Fax Number:	(865)523-4478
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	865-546-4305
Email:	mnapoleon@luedeka.com
Correspondent Name:	LUEDEKA NEELY GROUP, P.C.
Address Line 1:	PO BOX 1871
Address Line 4:	KNOXVILLE, TENNESSEE 37901
ATTORNEY DOCKET NUMBER:	72611.C1
NAME OF SUBMITTER:	J. DAVID GONCE
SIGNATURE:	/J. David Gonce/
DATE SIGNED:	02/07/2018
Total Attachments: 6	
source=72611us-topto-20180207-Assignment-Step2#page1.tif	
source=72611us-topto-20180207-Assignment-Step2#page2.tif	
source=72611us-topto-20180207-Assignment-Step2#page3.tif	
source=72611us-topto-20180207-Assignment-Step2#page4.tif	
source=72611us-topto-20180207-Assignment-Step2#page5.tif	
source=72611us-topto-20180207-Assignment-Step2#page6.tif	

EXHIBIT B
ASSIGNMENT OF PATENTS

BIOCELLULOSE ARZNEIMITTEL AG, a German corporation, whose address is Stadtsgrasse 2-16, 61118 Bad Vilbel, Germany ("Assignor"), hereby irrevocably sells, transfers, and assigns to INNOVATIVE PROTEINS CORPORATION, a Delaware corporation, whose address is 16192 Coastal Hwy, Lewes, Delaware, USA ("Assignee"), the entire right, title, and interest for the United States of America and its territorial possessions and all other countries and patent regions, including all rights of priority and rights to recover for past infringement, in the inventions disclosed in the patents and patent applications identified in Exhibit A, together with the entire right, title, and interest in and to all patents and patent applications identified in Exhibit A, all divisional, continuation, continuation-in-part, reissue, reexamination, extension or other applications based in whole or in part thereon, or which claim priority or are related by terminal disclaimer thereto or therefrom, and all Letters Patent of the United States and all other countries and patent regions worldwide which may or shall be granted on said inventions, or any parts thereof ("Assignment").

Assignor acknowledges having received consideration for this Assignment and agrees for said consideration to execute all deeds, separate written forms of assignment necessary to perfect the Assignment in specific countries and patent regions, or other instruments, and to do all acts reasonably necessary or proper to assist Assignee in securing the grant of Letters Patent in the United States and in all other countries and patent regions and to vest and confirm in Assignee, its successors and assigns, the legal title to all aforementioned inventions, patents, and patent applications.

Assignor does hereby authorize and request the Commissioner of Patents and Trademarks of the United States, and the equivalent authority in each other country and patent region in the world, to issue such Letters Patent as shall be granted upon said inventions or applications based thereon to Assignee, its successors and assigns.

[Remainder of page left intentionally blank.]



EXHIBIT A

Title "Method for the purification of G-CSF"

Applicant: Biocatalase Aztreonam/AG

Priority date: 15 July 2005

Country/Applicant Number/Agent/ Status

U.S.A. 11/985,678 pending in examination proceedings
Canada 2,614,820 granted, pending in examination proceedings
Europe 06 777 781 granted, pending in opposition proceedings
Germany (EP)06 777 781 validated
Austria (EP)06 777 781 validated
Belgium (EP)06 777 781 validated
Switzerland/Liechtenstein (EP)06 777 781 validated
Denmark (EP)06 777 781 validated
Spain (EP)06 777 781 validated
Finland (EP)06 777 781 validated
France (EP)06 777 781 validated
United Kingdom (EP)06 777 781 validated
Greece (EP)06 777 781 validated
Hungary (EP)06 777 781 validated
Ireland(EP)06 777 781 validated
Italy (EP)06 777 781 validated
Lithuania (EP)06 777 781 validated
Luxembourg (EP)06 777 781 validated
Netherlands (EP)06 777 781 validated
Poland (EP)06 777 781 validated
Portugal (EP)06 777 781 validated
Romania (EP)06 777 781 validated
Sweden (EP)06 777 781 validated
Turkey (EP)06 777 781 validated
Europe (Divisional)06 152 647 pending in examination proceedings
Germany (prior application) 10 2005 033 250 pending in examination proceedings



facsimile or electronic image transmission shall be binding to the same extent as an original signature page. Any Party that delivers a signature page by facsimile or electronic image transmission shall deliver an original counterpart to any other Party that requests such original counterpart.

7.8 Title of the Essence. Title is of the essence of this Agreement.

7.9 Interpretation. Article titles and headings to sections herein are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. The Exhibits referred to herein shall be construed with and as an integral part of this Agreement to the same extent as if they were set forth verbatim herein.

IN WITNESS WHEREOF, the Parties have executed this Agreement on the date first above written.

BIOCEUTICALS ARZNEIMITTEL AG

Date: July 04, 2011

By:

Name: Dr. Michael Mack
Title: CEO

By:

Name: Barbara Simon
Title: Financial

INNOVATIVE PROTEINS CORPORATION

Date: July 5, 2011

By:

Name: J.M. Engel
Title: Director

Patent Purchase and Assignment Agreement - Biocellulars Arzneimittel AG / Innovative Proteins Corporation

[Signature page for Biocellulars]

Witness my hand and seal this 09 day of July, 2011.

BIOCELLULARS ARZNEIMITTEL AG



Name: Dr. Michael Mack

Title: CEO



Name: Barbara Simon

Title: Finance

STATE OF _____

On this ___ day of _____, 2011, before me, the undersigned notary public, personally appeared _____, proved to me through satisfactory evidence of identification, which was, to be the person whose name is signed on this page.
Notary Public
~~My commission expires: _____~~

[Signature page for IPC]

Witness my hand and seal this 5th day of July, 2011.

INNOVATIVE PROTEINS CORPORATION

J.M. Szupel

Name: J. M. Szupel

Title: Director

STATE OF Delaware

On this 5 day of July, 2011, before me, the undersigned notary public, personally appeared J.M. Szupel, who proved to me through satisfactory evidence of identification, which was to be this Person whose name is signed on this page.
Notary Public [Signature]
My commission expires: 10/31/2010

PATENT

- design made somewhere else -

File No. 798/2011

I, the undersigned Dr. Werner Kunze, notary public of the city of D-61118 Bad Vilbel, hereby certifies, that

Dr. Michael Mack,
Barbara Simon,

residented at Stadastraße 2 - 18, 61118 Bad Vilbel, has signed personally in front of me the above attached signature.

Dr. Michael Mack and Barbara Simon are acting as Members of the Board of the company BIOCEUTICALS Arzneimittel AG, Stadastraße 2, 18, 61118 Bad Vilbel, registered in the commercial register of the Amtsgericht Frankfurt am Main - HRB 72513.

I, the undersigned Dr. Werner Kunze, notary public, hereby certify, that Dr. Michael Mack and Barbara Simon are authorized for the representation of the company BIOCEUTICALS Arzneimittel AG.

I, the undersigned Dr. Werner Kunze, notary public hereby attest the authorization of the representation by inspection of the commercial register of the Amtsgericht Frankfurt am Main - HRB 72513.

Dr. Michael Mack and Barbara Simon are personally known by the undersigned notary public.

Bad Vilbel, den 04. July 2011



W. Kunze
Dr. Kunze, notary